

Jianying Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2506368/publications.pdf>

Version: 2024-02-01

168
papers

6,978
citations

94433

37
h-index

76900

74
g-index

177
all docs

177
docs citations

177
times ranked

10331
citing authors

#	ARTICLE	IF	CITATIONS
1	Emergence of transferable ceftazidime-avibactam resistance in KPC-producing <i>Klebsiella pneumoniae</i> due to a novel CMY AmpC β -lactamase in China. <i>Clinical Microbiology and Infection</i> , 2022, 28, 136.e1-136.e6.	6.0	13
2	Analysis of clinical characteristics and prognosis of talaromycosis (with or without human) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Td	4.7	8
3	Metagenomic sequencing with spiked-in internal control to monitor cellularity and diagnosis of pneumonia. <i>Journal of Infection</i> , 2022, 84, e13-e17.	3.3	11
4	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2022, 28, 1127-1135.	7.0	9
5	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 411-422.	1.1	70
6	Asthma Management Using the Mobile Asthma Evaluation and Management System in China. <i>Allergy, Asthma and Immunology Research</i> , 2022, 14, 85.	2.9	4
7	Allergic Bronchopulmonary Mycosis Caused by <i>Mucor</i> Overlapping With Invasive Pulmonary Mucormycosis: A Case Report. <i>Frontiers in Medicine</i> , 2022, 9, 831213.	2.6	0
8	Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 708-717.	1.1	11
9	IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C814-C824.	4.6	10
10	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. <i>Journal of Thoracic Oncology</i> , 2022, 17, 816-826.	1.1	15
11	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	9.4	30
12	Benzo[a]pyrene inhibits myoblast differentiation through downregulating the Hsp70-MK2-p38MAPK complex. <i>Toxicology in Vitro</i> , 2022, 82, 105356.	2.4	2
13	TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non-Small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	2.3	1
14	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. <i>Journal of Clinical Oncology</i> , 2022, 40, 3162-3171.	1.6	76
15	Th22 Cells/IL-22 Serves as a Protumor Regulator to Drive Poor Prognosis through the JAK-STAT3/MAPK/AKT Signaling Pathway in Non-Small-Cell Lung Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-12.	2.2	6
16	Deguelin Attenuates Non-Small-Cell Lung Cancer Cell Metastasis by Upregulating PTEN/KLF4/EMT Signaling Pathway. <i>Disease Markers</i> , 2022, 2022, 1-10.	1.3	3
17	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211032.	1.3	2
18	SAF-189s in advanced, ALK-positive, non-small cell lung cancer: Results from a first-in-human phase 1/2, multicenter study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9076-9076.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Abstract CT538: Tepotinib + gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT. <i>Cancer Research</i> , 2022, 82, CT538-CT538.	0.9	2
20	Abstract CT552: RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 years. <i>Cancer Research</i> , 2022, 82, CT552-CT552.	0.9	0
21	Abstract CT555: Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China study. <i>Cancer Research</i> , 2022, 82, CT555-CT555.	0.9	0
22	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9015-9015.	1.6	6
23	Phase I study of the efficacy and safety of IBI319 in patients with advanced malignant tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2646-2646.	1.6	1
24	Bloodstream Infections due to Carbapenem-Resistant Klebsiella pneumoniae: A Single-Center Retrospective Study on Risk Factors and Therapy Options. <i>Microbial Drug Resistance</i> , 2021, 27, 227-233.	2.0	15
25	Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 299-309.	1.1	72
26	Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 619-631.	4.2	80
27	Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE042 China Study. <i>International Journal of Cancer</i> , 2021, 148, 2313-2320.	5.1	60
28	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (Camel): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 305-314.	10.7	277
29	Loss of LIMCH1 predicts poor prognosis in patients with surgically resected Lung Adenocarcinoma: A study based on Immunohistochemical Analysis and Bioinformatics. <i>Journal of Cancer</i> , 2021, 12, 181-189.	2.5	7
30	Hyperlipidemia Caused by Voriconazole: A Case Report. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 483-487.	2.7	0
31	Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. <i>Lancet</i> , 2021, 397, 499-509.	13.7	119
32	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment. <i>Medicine (United States)</i> , 2021, 100, e23712.	1.0	4
33	Efficacy of different antifungal drugs as initial treatment for patients with talaromycosis: A systematic review and meta-analysis. <i>Journal De Mycologie Medicale</i> , 2021, 31, 101108.	1.5	3
34	A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib. <i>Clinical Lung Cancer</i> , 2021, 22, e799-e803.	2.6	2
35	Clinical Characteristics of Chronic Lung Abscess Associated with Parvimonas micra Diagnosed Using Metagenomic Next-Generation Sequencing. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1191-1198.	2.7	6
36	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , 2021, 154, 176-185.	2.0	18

#	ARTICLE	IF	CITATIONS
37	Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 680191.	2.8	16
38	Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019. <i>Journal of Medical Virology</i> , 2021, 93, 4446-4453.	5.0	7
39	Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3513-3524.	4.2	26
40	Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. <i>Translational Lung Cancer Research</i> , 2021, 10, 1819-1828.	2.8	7
41	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 709.	7.1	185
42	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9008-9008.	1.6	30
43	RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9102-9102.	1.6	2
44	HIV-negative case of <i>Talaromyces marneffei</i> pulmonary infection with a TSC2 mutation. <i>Journal of International Medical Research</i> , 2021, 49, 0300060521110167.	1.0	3
45	Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases. <i>Frontiers in Oncology</i> , 2021, 11, 619371.	2.8	7
46	International consensus on severe lung cancer—the first edition. <i>Translational Lung Cancer Research</i> , 2021, 10, 2633-2666.	2.8	6
47	Culture-Related Health Disparities in Quality of Life: Assessment of Instrument Dimensions Among Chinese. <i>Frontiers in Public Health</i> , 2021, 9, 663904.	2.7	6
48	Gremlin2 Activates Fibroblasts to Promote Pulmonary Fibrosis Through the Bone Morphogenic Protein Pathway. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 683267.	3.5	5
49	Clinical Impact of Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage in the Diagnosis and Management of Pneumonia. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1259-1268.	2.8	43
50	Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14). <i>Cancer Research</i> , 2021, 81, CT158-CT158.	0.9	4
51	Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC). <i>Cancer Research</i> , 2021, 81, CT041-CT041.	0.9	3
52	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	1.1	26
53	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2109-2120.	1.1	75
54	Icotinib versus chemotherapy as adjuvant treatment for stage II-III EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1021-1029.	10.7	93

#	ARTICLE	IF	CITATIONS
55	Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China. <i>Respiratory Medicine</i> , 2021, 186, 106522.	2.9	8
56	Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1512-1522.	1.1	127
57	Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Non-small-Cell Lung Cancer in KEYNOTE-407. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100225.	1.1	13
58	Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). <i>Journal of Thoracic Oncology</i> , 2021, 16, 1501-1511.	1.1	158
59	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1154-1164.	10.7	107
60	VIRMA contributes to non-small cell lung cancer progression via N6-methyladenosine-dependent DAPK3 post-transcriptional modification. <i>Cancer Letters</i> , 2021, 522, 142-154.	7.2	29
61	The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199296.	3.2	40
62	A novel stilbene derivative (GMQ3) suppressed proliferation and induced apoptosis in lung cancer via the p38-MAPK/SIRT1 pathway. <i>Biochemical Pharmacology</i> , 2021, 193, 114808.	4.4	1
63	Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 355.	17.1	45
64	Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 374.	17.1	7
65	Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 760097.	2.8	9
66	ETV4 mediated lncRNA C2CD4D-AS1 overexpression contributes to the malignant phenotype of lung adenocarcinoma cells via miR-3681-3p/NEK2 axis. <i>Cell Cycle</i> , 2021, 20, 2607-2618.	2.6	5
67	Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events. <i>Frontiers in Oncology</i> , 2021, 11, 757069.	2.8	9
68	Microbiological and clinical characteristics of cryptococemia: a retrospective analysis of 85 cases in a Chinese hospital. <i>Medical Mycology</i> , 2020, 58, 478-484.	0.7	11
69	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 45-53.	10.7	105
70	First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder. <i>Journal of Affective Disorders</i> , 2020, 277, 337-340.	4.1	56
71	Overexpression of KIAA0101 Promotes the Progression of Non-small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 6663-6674.	2.5	3
72	Secondary Bacterial Infections in Critical Ill Patients With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa220.	0.9	66

#	ARTICLE	IF	CITATIONS
73	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020, 150, 240-246.	2.0	10
74	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) <i>Tj ETQq0 0 1rgBT /Overlock 10</i>		
75	Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study. <i>Lung Cancer</i> , 2020, 147, 130-136.	2.0	8
76	Translation: Management of Coronavirus Disease 2019 (COVID-19): Experience in Zhejiang Province, China. <i>Infectious Microbes & Diseases</i> , 2020, 2, 55-63.	1.3	16
77	Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature. <i>Immunotherapy</i> , 2020, 12, 957-964.	2.0	7
78	Predicting Survival Across Acute Exacerbation of Interstitial Lung Disease in Patients with Idiopathic Inflammatory Myositis: The GAP-ILD Model. <i>Rheumatology and Therapy</i> , 2020, 7, 967-978.	2.3	7
79	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	1.1	85
80	Dioscin facilitates ROS-induced apoptosis via the p38-MAPK/HSP27-mediated pathways in lung squamous cell carcinoma. <i>International Journal of Biological Sciences</i> , 2020, 16, 2883-2894.	6.4	27
81	Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e150-e153.	1.1	2
82	Discovery of a Novel Hypervirulent <i>Acinetobacter baumannii</i> Strain in a Case of Community-Acquired Pneumonia. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 1147-1153.	2.7	5
83	Teplotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 169</i>	10.7	169
84	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2020, 146, 209-216.	2.0	2
85	Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. <i>Critical Care</i> , 2020, 24, 299.	5.8	85
86	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. <i>Lung Cancer</i> , 2020, 146, 252-262.	2.0	12
87	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1015-1026.	1.1	58
88	First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 509-519.e1.	2.6	3
89	Dioscin elicits anti-tumour immunity by inhibiting macrophage M2 polarization via JNK and STAT3 pathways in lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9217-9230.	3.6	42
90	Triptolide induces atrophy of myotubes by triggering IRS-1 degradation and activating the FoxO3 pathway. <i>Toxicology in Vitro</i> , 2020, 65, 104793.	2.4	7

#	ARTICLE	IF	CITATIONS
91	Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. <i>BMJ</i> , The, 2020, 369, m1443.	6.0	1,226
92	Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). <i>Journal of Clinical Oncology</i> , 2020, 38, 9519-9519.	1.6	50
93	Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, 9554-9554.	1.6	4
94	A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, e21618-e21618.	1.6	8
95	SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study. <i>Journal of Clinical Oncology</i> , 2020, 38, e21689-e21689.	1.6	5
96	Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas. <i>Oncology Letters</i> , 2020, 20, 2987-2996.	1.8	1
97	Risk factors for acquisition and mortality of multidrug-resistant <i>Acinetobacter baumannii</i> bacteremia. <i>Medicine (United States)</i> , 2019, 98, e14937.	1.0	50
98	Sec3 knockdown inhibits TGF- β 2 induced epithelial-mesenchymal transition through the down-regulation of Akt phosphorylation in A549 cells. <i>Biochemical and Biophysical Research Communications</i> , 2019, 519, 253-260.	2.1	1
99	Virulence and genomic features of a <i>CTX-M-3</i> and <i>CTX-M-14</i> coharboring hypermucoviscous <i>Klebsiella pneumoniae</i> of serotype K2 and ST65. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 145-159.	2.7	13
100	New insights into early intervention of chronic obstructive pulmonary disease with mild airflow limitation. <i>International Journal of COPD</i> , 2019, Volume 14, 1119-1125.	2.3	14
101	Particulate matter with a diameter of $\approx 2.5 \mu\text{m}$ induces and enhances bleomycin-induced pulmonary fibrosis by stimulating endoplasmic reticulum stress in rat. <i>Biochemistry and Cell Biology</i> , 2019, 97, 357-363.	2.0	9
102	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 437-446.	10.7	192
103	Template-ready PCR method for detection of human telomerase reverse transcriptase mRNA in sputum. <i>Analytical Biochemistry</i> , 2019, 577, 34-41.	2.4	2
104	Hypoxia-inducible factor-1 signaling pathway influences the sensitivity of HCC827 cells to gefitinib. <i>Oncology Letters</i> , 2019, 17, 4034-4043.	1.8	6
105	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	1.1	260
106	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 989-999.	2.8	28
107	Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, 9091-9091.	1.6	5
108	Epithelial-mesenchymal transition phenotype of circulating tumor cells is associated with distant metastasis in patients with NSCLC. <i>Molecular Medicine Reports</i> , 2019, 19, 601-608.	2.4	19

#	ARTICLE	IF	CITATIONS
109	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	6.4	192
110	Serum <i>Aspergillus fumigatus</i> -specific IgG antibody decreases after antifungal treatment in chronic pulmonary aspergillosis patients. <i>Clinical Respiratory Journal</i> , 2018, 12, 1772-1774.	1.6	6
111	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1405-1411.	1.6	230
112	Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2-FGFR1 autocrine loop. <i>Cancer Medicine</i> , 2018, 7, 6205-6218.	2.8	13
113	Evaluation of a quantitative serum <i>Aspergillus fumigatus</i> -specific IgM assay for diagnosis of chronic pulmonary aspergillosis. <i>Clinical Respiratory Journal</i> , 2018, 12, 2566-2572.	1.6	8
114	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 32-37.	2.0	32
115	Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment. <i>BMC Cancer</i> , 2018, 18, 10.	2.6	28
116	Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. <i>Cancer Letters</i> , 2018, 436, 1-9.	7.2	18
117	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	1.1	146
118	The characteristic of asthma control among nasal diseases population: Results from a cross-sectional study. <i>PLoS ONE</i> , 2018, 13, e0191543.	2.5	6
119	SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition. <i>Oncotarget</i> , 2018, 9, 10891-10904.	1.8	23
120	Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/ β -catenin signaling pathway. <i>BMC Cancer</i> , 2017, 17, 161.	2.6	38
121	Significant Radiologic Response of Pancreatic Metastasis After Targeted Therapy of Ceritinib (LDK378) for ALK-Rearranged Lung Adenocarcinoma Presenting With Hyperglycemia. <i>Oncology Research</i> , 2017, 25, 545-550.	1.5	1
122	FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas. <i>Thoracic Cancer</i> , 2017, 8, 655-665.	1.9	23
123	Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer. <i>Cancer Letters</i> , 2017, 408, 130-137.	7.2	37
124	Combination of Tigecycline and Levofloxacin for Successful Treatment of Nosocomial Pneumonia Caused by New Delhi Metallo- β -Lactamase-1-Producing <i>Raoultella planticola</i> . <i>Microbial Drug Resistance</i> , 2017, 23, 127-131.	2.0	15
125	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. <i>Oncotarget</i> , 2017, 8, 66293-66304.	1.8	11
126	Deguelin Attenuates Allergic Airway Inflammation via Inhibition of NF- κ B Pathway in Mice. <i>International Journal of Biological Sciences</i> , 2017, 13, 492-504.	6.4	20

#	ARTICLE	IF	CITATIONS
127	Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study. <i>Journal of Thoracic Disease</i> , 2017, 9, 5068-5074.	1.4	20
128	Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 studyâ€”Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9053-9053.	1.6	10
129	Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients. <i>Oncotarget</i> , 2017, 8, 108840-108847.	1.8	5
130	Deguelin Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells through Regulating the Expression of Galectin-1. <i>International Journal of Biological Sciences</i> , 2016, 12, 850-860.	6.4	23
131	Primary pulmonary chondrosarcoma and a fast-growing mass that accidentally mimicked teratoma. <i>Journal of Thoracic Disease</i> , 2016, 8, E947-E951.	1.4	2
132	High Prevalence of ESBL-Producing <i>Klebsiella pneumoniae</i> Causing Community-Onset Infections in China. <i>Frontiers in Microbiology</i> , 2016, 7, 1830.	3.5	50
133	TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer. <i>Oncotarget</i> , 2016, 7, 29620-29634.	1.8	32
134	IL-17A-producing T cells are associated with the progression of lung adenocarcinoma. <i>Oncology Reports</i> , 2016, 36, 641-650.	2.6	26
135	Regulation of Viral Infection-induced Airway Remodeling Cytokine Production by the TLR3-EGFR Signaling Pathway in Human Bronchial Epithelial Cells. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 750-755.	1.6	8
136	A potential target gene for the host-directed therapy of mycobacterial infection in murine macrophages. <i>International Journal of Molecular Medicine</i> , 2016, 38, 823-833.	4.0	7
137	HB-EGFâ€”Promoted Airway Smooth Muscle Cells and Their Progenitor Migration Contribute to Airway Smooth Muscle Remodeling in Asthmatic Mouse. <i>Journal of Immunology</i> , 2016, 196, 2361-2367.	0.8	21
138	Phase 3 study of first-line crizotinib vs pemetrexedâˆ”cisplatin/carboplatin (PCC) in East Asian patients (pts) with <i>ALK</i> + advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9058-9058.	1.6	7
139	Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIa non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8570-TPS8570.	1.6	2
140	A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features. <i>PLoS ONE</i> , 2016, 11, e0161861.	2.5	8
141	Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis. <i>Oncotarget</i> , 2016, 7, 63758-63766.	1.8	7
142	Advanced lung adenocarcinomas with <i>ROS1</i> -rearrangement frequently show hepatoid cell. <i>Oncotarget</i> , 2016, 7, 74162-74170.	1.8	15
143	Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis. <i>Oncology Reports</i> , 2015, 33, 478-484.	2.6	24
144	Current small cell lung cancer treatment in China. <i>Thoracic Cancer</i> , 2015, 6, 233-238.	1.9	26

#	ARTICLE	IF	CITATIONS
145	A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report. <i>Oncology Letters</i> , 2015, 10, 1575-1578.	1.8	20
146	Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. <i>Thoracic Cancer</i> , 2015, 6, 216-219.	1.9	13
147	Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review. <i>Oncology Letters</i> , 2015, 9, 2041-2045.	1.8	4
148	Diffuse alveolar hemorrhage due to metastatic angiosarcoma of the lung: A case report. <i>Oncology Letters</i> , 2015, 10, 3853-3855.	1.8	4
149	Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis. <i>Journal of Medical Microbiology</i> , 2015, 64, 702-707.	1.8	58
150	Interleukin-10 Promoter Gene Polymorphisms and Susceptibility to Tuberculosis: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0127496.	2.5	19
151	Clinical Analysis of Percutaneous Computed Tomography-Guided Hook Wire Localization of 168 Small Pulmonary Nodules. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1861-1867.	1.3	27
152	Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT. <i>BMC Pulmonary Medicine</i> , 2015, 15, 20.	2.0	17
153	IL-17A, But Not IL-17F, Is Indispensable for Airway Vascular Remodeling Induced by Exaggerated Th17 Cell Responses in Prolonged Ovalbumin-Challenged Mice. <i>Journal of Immunology</i> , 2015, 194, 3557-3566.	0.8	23
154	Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger. <i>PLoS ONE</i> , 2015, 10, e0136659.	2.5	13
155	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0142500.	2.5	14
156	Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3344-8.	0.5	2
157	Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 19689-700.	1.3	4
158	Association between Tumor Necrosis Factor- α rs1800629 Polymorphism and Risk of Asthma: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e99962.	2.5	16
159	Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening. <i>PLoS ONE</i> , 2014, 9, e92828.	2.5	42
160	Characterization of a Novel Plasmid Type and Various Genetic Contexts of blaOXA-58 in <i>Acinetobacter</i> spp. from Multiple Cities in China. <i>PLoS ONE</i> , 2014, 9, e84680.	2.5	52
161	Clinical and Radiographic Characteristics of Pulmonary Nocardiosis: Clues to Earlier Diagnosis. <i>PLoS ONE</i> , 2014, 9, e90724.	2.5	49
162	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. <i>Journal of Thoracic Disease</i> , 2014, 6, 958-64.	1.4	9

#	ARTICLE	IF	CITATIONS
163	Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?. <i>Lancet Oncology</i> , The, 2013, 14, e438.	10.7	4
164	Triggering receptor expressed on myeloid cells-2 (TREM-2) elicited by lung cancer cells to facilitate tumor immune evasion.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22054-e22054.	1.6	2
165	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7559-7559.	1.6	4
166	Linezolid combined with trimethoprimâ€“sulfamethoxazole therapy for the treatment of disseminated nocardiosis. <i>Journal of Medical Microbiology</i> , 2011, 60, 1043-1045.	1.8	7
167	Genomic Analysis of the Multidrug-Resistant <i>Acinetobacter baumannii</i> Strain MDR-ZJ06 Widely Spread in China. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4506-4512.	3.2	116
168	The Overexpression of Heparin-Binding Epidermal Growth Factor Is Responsible for Th17-Induced Airway Remodeling in an Experimental Asthma Model. <i>Journal of Immunology</i> , 2010, 185, 834-841.	0.8	65